SAFINAMIDE (Xadago®)

Clinical Indication

Parkinson’s Disease

Date of classification

August 2018

Review date

August 2021

Amber SIMPLE

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.